Supplemental material
Future Oncology
Volume 19, 2023 - Issue 2
Research Article
Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer
Silv Fu1 Department of Oncology,The First Affiliated Hospital of Nanchang University,Nanchang,330006,China;2 Department of Radiotherapy,Jiangxi Cancer Hospital,Nanchang,330029,China
https://orcid.org/0000-0002-0069-0115View further author information
https://orcid.org/0000-0002-0069-0115View further author information, Hongxiang Huang1 Department of Oncology,The First Affiliated Hospital of Nanchang University,Nanchang,330006,Chinahttps://orcid.org/0000-0002-4446-7775View further author information
https://orcid.org/0000-0002-4446-7775View further author information, , , , , , , , & show all